


ISSUE DATE August 31, 2015	EFFECTIVE DATE September 1, 2015	NUMBER 01-15-29, 08-15-29, 09-15-29, 31-15-29, 33-15-28
SUBJECT Addition to the Medical Assistance Program Fee Schedule for Administration of HPV 9 Vaccine	BY  Leesa M. Allen, Deputy Secretary Office of Medical Assistance Programs	

IMPORTANT REMINDER: On **October 1, 2015**, the ICD-9 code sets used to report medical diagnoses and inpatient procedures will be replaced by ICD-10 code sets. Additional information is available on the Department of Human Services website at:

http://www.dhs.state.pa.us/provider/icd10information/P_012571

IMPORTANT REMINDER: All providers (including all associated service locations - 13 digits) who enrolled on or before **March 25, 2011** must revalidate their enrollment information no later than **March 24, 2016**. New enrollment application including all revalidation requirements may be found at http://www.dhs.state.pa.us/provider/promise/enrollmentinformation/S_001994. Please send in your application(s) as soon as possible.

PURPOSE:

The purpose of this bulletin is to inform providers enrolled in the Medical Assistance (MA) Program that the Department of Human Services (Department) added procedure code 90651 for the administration of the human papillomavirus (HPV) 9-valent vaccine (Gardasil 9®) for MA eligible beneficiaries for dates of service on and after September 1, 2015.

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, outpatient hospitals and independent medical surgical clinics enrolled in the MA Program who administer immunizations to MA beneficiaries in the MA Fee-For-Service delivery system and the MA Managed Care delivery system. Providers rendering services to MA beneficiaries under the MA Managed Care delivery system should address any coding or rate-related questions to the appropriate managed care organization (MCO).

BACKGROUND:

On December 10, 2014, the U.S. Food and Drug Administration (FDA) approved Gardasil 9® (human papillomavirus 9-valent vaccine, recombinant) for the prevention of

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll free number for your provider type

Visit the Office of Medical Assistance Programs Web site at
<http://www.dhs.state.pa.us/provider/healthcaremedicalassistance/index.htm>

certain diseases caused by nine types of HPV. By covering nine HPV types, five more HPV types than Gardasil previously approved by the FDA, Gardasil 9® has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.

Gardasil 9® is a vaccine approved for use in females 9 through 26 years of age and males 9 through 15 years of age. It is approved for the prevention of cervical, vulvar, vaginal and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, and for the prevention of genital warts caused by HPV types 6 or 11. Gardasil 9® adds protection against five additional HPV types, 31, 33, 45, 52 and 58, which cause approximately 20 percent of cervical cancers and are not covered by previously FDA-approved HPV vaccines.

Complete Vaccination Recommendations of the Advisory Committee on Immunization Practices (ACIP) for Gardasil 9® may be obtained from the Centers for Disease Control and Prevention website at:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm>.

DISCUSSION:

Effective May 25, 2015, the Pennsylvania Department of Health (DOH) added HPV 9-valent, Gardasil 9®, to the 2015 list of vaccines available to providers enrolled in the Vaccines for Children (VFC) Program. VFC's provider enrollment process is found on the DOH website at:

http://www.health.pa.gov/My%20Health/Immunizations/Vaccines-for-Children/Documents/New_Section_2_%20A_Enrollment_2015.pdf

To allow providers enrolled in the MA Program to bill the Department for the administration of the HPV 9 vaccine, the MA Program added CPT 90651 (human papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (HPV), 3 dose schedule, for intramuscular use) to the Outpatient Fee Schedule, under MA Bulletin 99-15-06, "2015 HCPCS Updates and Other Procedure Code Changes", effective September 1, 2015. The Outpatient Fee Schedule is available at:

<http://www.dhs.state.pa.us/publications/forproviders/schedules/mafeeschedules/index.htm>.

PROCEDURE:

Effective for dates of service on and after September 1, 2015, MA providers should bill the Department for the administration of the Gardasil 9® vaccine to MA eligible beneficiaries using the CPT code 90651. For dates of service, prior to September 1, 2015, providers should bill the Department for the administration of Gardasil 9® using CPT code 90749 (unlisted immunization procedure). MA providers should refer to MAB 99-15-06 for the addition of procedure code 90651 to the Outpatient Fee Schedule.

The MA fee for the administration of each vaccine is \$10.00 per administration. Providers participating in an MA MCO network must abide by payment arrangements as stated in their individual MCO contract.

The Pennsylvania DOH VFC Program includes Gardasil 9® on the 2015 list of vaccines available at no cost to VFC enrolled providers for administration to children, including MA eligible children, under 19 years of age. Therefore, the MA Program will pay for Gardasil 9® vaccine only for MA-eligible beneficiaries who are 19 years of age and older consistent with the indicated use of the vaccine by the FDA and current ACIP recommendations.

MA providers may bill the Department for HPV 9-valent (Gardasil 9®) vaccine for MA eligible beneficiaries who are 19 years of age and older by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers may access the online version of the MA Drug Fee Schedule under the Department's website at:

<http://www.dhs.state.pa.us/publications/forproviders/schedules/drugfeeschedule/index.htm>.